AllAnalyst Report
Morningstar•March 29, 2024
Morningstar•March 29, 2024Smith & Nephew plc: Smith & Nephew Racks Up Consistent Operational Gains
Summary
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total reven
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: ResMed Inc.Apr 26, 2024 •
RMD
- RMD: Lowering target price to $193.00Apr 24, 2024 •
RMD
- TFX: Raising target price to $222.00Apr 24, 2024 •
TFX
- GMED: What does Argus have to say about GMED?Apr 24, 2024 •
GMED
- CNMD: Lowering target price to $75.00Apr 24, 2024 •
CNMD
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.